Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
Fabrice Cognasse, Director of Research – Scientific Director at The EFS in Auvergne-Rhône-Alpes and INSERM, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Transfusion Journal, adding:
“Cold-stored platelets: moving from enthusiasm to product design
We are pleased to share our last publication published in Blood Transfusion Journal.
‘Cold platelets, redefined: pathogen reduction without surrendering hemostatic intent.’
In their timely and original study, Teresa Jimenez-Marco et al. show that riboflavin/UV pathogen reduction does not erase the defining haemostatic signature of cold-stored platelets—namely, faster clot initiation.
However, their findings also reveal an important trade-off: a reduction in clot strength at the end of the 14-day storage period.
These results move the field beyond a simplistic opposition between safety and function.
Cold storage combined with pathogen reduction does not produce uniformly ‘better’ or ‘worse’ platelets, but rather a distinct platelet product, whose biological and haemostatic properties evolve over time.
The key question is therefore no longer:
Which platelet product is best overall?
It is: Which platelet product is best for which patient, for which indication, and at which point during storage?
This work supports the development of diversified, purpose-built platelet inventories tailored to clinical needs—bringing us closer to the right platelet product, for the right patient, at the right time.
Congratulations to Jimenez-Marco and colleagues for this valuable contribution, and many thanks to Blood Transfusion Journal for highlighting this important and rapidly evolving area of transfusion medicine.”
Title: Cold platelets, redefined: pathogen reduction without surrendering hemostatic intent
Authors: Fabrice Cognasse, Hind Hamzeh Cognasse, Jose Maria Garcia-Gala, Konstanze Aurich
Title: Comparison between cold-stored platelets treated with riboflavin and UV light versus untreated cold-stored platelets
Authors: Teresa Jimenez-Marco, Natalia Torres-Reverte, Miguel Quetglas-Oliver, Daniel Morell-Garcia, Carme Ballester-Servera
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 16:44The Evolving Treatment Landscape of Hemophilia: From Factor Replacement to Gene Therapy
-
Aug 11, 2026, 16:34Advancing Hemophilia Care Through Training and Local Capacity Building – WFH
-
Aug 11, 2026, 16:26Sabrina H.: The Spectrum of PF4-Mediated Thrombotic Disorders
-
Aug 11, 2026, 16:17Mandy Lauw: From CRTH Training to Clinical Trials
-
Aug 11, 2026, 16:05Obi Light Ogbonnia: From 52 Years of Living With Sickle Cell to a Global Stage
-
Aug 11, 2026, 15:42Iva Pruner: Hemostasis, Thrombosis, and a Little Death Metal
-
Aug 11, 2026, 15:25Bradley Maron։ The AI Revolution in Cardiovascular Drug Development
-
Aug 11, 2026, 15:10Jared Rice: When a Negative DAT Doesn’t Mean the Alloimmune Risk Is Gone
-
Aug 11, 2026, 14:58Manuel De Jesus: Validating the Future of Point-of-Care Anemia Monitoring